Skip to content

Rheumatoid arthritis — genetics, environment and mucosal origins

TL;DR — RA is polygenic: heritability is commonly estimated near 60%, with the strongest association in HLA class II and many smaller immune-locus effects (Dedmon 2020, PMID 32638005). Genetic architecture differs most clearly by ACPA status. Smoking is the best-established modifiable exposure, especially for ACPA-positive RA in genetically susceptible people, while silica and some reproductive/metabolic factors contribute smaller or less certain effects. Lung, periodontal, and gut mucosa are candidate sites where environmental exposure, microbial communities, and protein modification could breach tolerance, but association does not yet establish a single mucosal origin (Lucchino 2019, PMID 31295951; Möller 2020, PMID 32582191). Genetics and exposures explain risk distributions, not individual destiny, and no current genetic or microbiome test diagnoses RA.

Genetic architecture

Component Evidence Clinical meaning
HLA-DRB1 shared epitope Strongest common genetic association, especially ACPA-positive RA Susceptibility and some phenotype information; not diagnostic
Other HLA class II alleles Population- and serotype-specific effects Ancestry affects transferability
PTPN22 Non-HLA immune-regulation locus Small individual effect
STAT4 Cytokine-signaling association Shared across autoimmune diseases
CTLA4 T-cell costimulation association Mechanistically coherent but nondeterministic
TRAF1/C5 Immune signaling/complement region Common-variant risk contribution
TNFAIP3 NF-κB regulation Pleiotropic autoimmunity locus
Polygenic burden Sum of many small effects Research stratification; limited clinical calibration

Family and twin studies support a substantial inherited component; large GWAS show that this is distributed across many variants rather than a Mendelian pattern (Dedmon 2020, PMID 32638005). HLA-DR molecules present peptides to CD4 T cells, linking genetic susceptibility to antigen-specific tolerance. Shared-epitope alleles have their strongest and most consistent association with ACPA-positive disease (van Heemst 2014, PMID 24813459).

Gene–environment interaction

Smoking and HLA shared-epitope carriage interact most strongly in ACPA-positive RA models. Biological plausibility includes airway inflammation, protein citrullination, and altered immune presentation, but observational interaction estimates are sensitive to smoking dose, timing, ancestry, and control selection (Lucchino 2019, PMID 31295951).

Exposure Evidence direction Confidence/caveat
Cigarette smoking Increased risk, strongest for ACPA-positive RA Established association; cessation-specific prevention effect unproven
Occupational silica Increased risk in exposed populations Exposure assessment and co-smoking confounding
Air pollution Possible increased risk Heterogeneous pollutants and ecological exposure
Periodontitis Associated with prevalent and incident RA Bidirectionality and smoking confounding
Obesity Modest increased risk and worse outcomes Sex, activity, and treatment-response confounding
Microbial dysbiosis Repeated case-control differences Medication, diet, geography and oral-health confounding
Hormonal/reproductive factors Sex-pattern plausibility; mixed estimates Strong cohort and era dependence
Infection Candidate triggers, no universal pathogen Temporal and causal inconsistency

The lung hypothesis

The lung can show local citrullination and ACPA-related immune activity before joint disease; smoking and inhaled particles provide plausible triggers. RA-related airway and interstitial abnormalities may precede articular RA in some people, while in others lung disease follows years of joint disease (Kadura 2021, PMID 34168062; Kim 2023, PMID 37833957).

This supports “a lung” origin for a subset, not “the lung” origin for all RA. Seronegative RA, never-smokers, and divergent mucosal signatures argue for multiple routes.

Periodontium and oral organisms

Periodontitis shares smoking, age and socioeconomic determinants with RA. Porphyromonas gingivalis expresses a peptidylarginine deiminase; Aggregatibacter actinomycetemcomitans has been linked to neutrophil hypercitrullination. These mechanisms make the oral cavity a plausible tolerance-breaking site, but intervention evidence has not shown that periodontal treatment prevents RA (Möller 2020, PMID 32582191).

Causal test Current status
Temporality before autoantibodies Demonstrated inconsistently
Dose-response Variable by periodontal definition
Specific microbial mechanism Plausible laboratory evidence
Removal reverses autoimmunity Not established
Prevention trial No definitive RA-onset trial

Gut microbiome

RA cohorts often differ from controls in gut taxa and function, and immune-active metabolites provide mechanistic routes to systemic autoimmunity. Yet microbiome results are unusually vulnerable to diet, geography, sequencing pipeline, oral contamination, stool handling, and treatment. Methotrexate and other DMARDs can alter microbial composition, making cross-sectional “RA signatures” partly consequences of disease or therapy (Möller 2020, PMID 32582191; Qi 2025, PMID 40825448).

No fecal, oral, or combined microbial signature has adequate external validation for diagnosis, prognosis, or treatment choice. Probiotic, antibiotic, and dietary studies should be considered experimental rather than disease-modifying RA therapy.

Protein modification and autoantigens

Citrullination converts arginine residues through peptidylarginine deiminase activity and can create antigens recognized by ACPA. Carbamylation and acetylation provide additional post-translationally modified antigen systems. Neutrophil extracellular traps, mucosal inflammation, and cell death can expose modified proteins (Frade-Sosa 2023, PMID 37867028).

Autoantibody maturation—higher titers, expanding specificity, altered glycosylation, and epitope spreading—may mark transition toward arthritis. It remains unclear which changes are causal and which are readouts of an already-evolving immune network.

Why individual prediction remains difficult

Limitation Consequence
Small effect sizes for most variants Low positive predictive value alone
Ancestry imbalance in GWAS Poor transfer across populations
Exposure misclassification Biased interaction estimates
Seropositive/seronegative pooling Blurred causal architecture
Time-varying microbiome and immunity One sample may not represent trajectory
Referral enrichment Inflated risk in specialty cohorts
Treatment effects Reverse causation in established RA studies

Translational implications

Genetic and exposure findings currently support population research, smoking cessation, occupational protection, and risk-enriched prevention studies. They do not support withholding or selecting a DMARD from HLA or microbiome data. Precision treatment requires prospective demonstration that a biomarker-by-treatment interaction improves outcomes, not merely association with response (Aletaha 2020, PMID 32276742; Bhamidipati 2022, PMID 35248489).

Quantified causal evidence and its limits

Candidate determinant Quantitative or mechanistic result Causal caution
Inherited liability Japanese twin data estimated heritability at 62.2% in an AE model and 56.1% in an ACE model; 4/43 monozygotic versus 1/43 dizygotic co-twins had RA (Terao 2016, PMID 26727555). Wide uncertainty from few concordant pairs; heritability is population- and environment-specific.
Smoking × HLA Among 1,590 ACPA-positive cases, 891 ACPA-negative cases and 1,856 controls, 102 smoking-interacting SNPs passed correction, all in HLA; none did for ACPA-negative RA (Jiang 2016, PMID 26272072). Interaction depends on exposure measurement and ancestry; it does not predict an individual outcome.
Silica Occupational exposure was associated with RA (pooled OR 2.59, 95% CI 1.73–3.45); among smokers the pooled OR was 2.49 (1.13–3.86) (Mehri 2020, PMID 32596007). Job-exposure matrices, smoking, and healthy-worker selection remain sources of bias; an independent review also found substantial study heterogeneity (Morotti 2022, PMID 33651342).
Periodontitis Thirteen studies, 706,611 exposed and 349,983 controls: pooled RA OR 1.69 (95% CI 1.31–2.17) (Qiao 2020, PMID 32593704). Bidirectionality and common causes prevent interpreting periodontal treatment as RA prevention.
Gut diversity For RA, observed-species diversity SMD −0.51 (95% CI −0.78 to −0.24) and Shannon diversity SMD −0.31 (−0.49 to −0.13) (Wang 2022, PMID 35594658). Shared depletion of butyrate producers across diseases argues against an RA-specific diagnostic signature.

The mucosal-origin hypothesis is biologically plural. Local lung ACPA, airway abnormalities, sputum hypercellularity and NET formation occur in some at-risk individuals, yet local mucosal autoantibody production is more common than progression to RA; Holers and colleagues therefore proposed that some mucosal ACPA may initially be protective rather than pathogenic (Holers 2018, PMID 30111803). Population twin work likewise indicates that shared environment and genes contribute differently by serologic subset (Svendsen 2013, PMID 23468964). These data support multiple routes to tolerance loss, not a single organism, tissue, or exposure.

Evidence map

This map adds directly adjacent evidence used to bound interpretation. Inclusion means the record informs this topic or a tightly linked decision; it does not imply that every study supports every conclusion on the page.

Adjacent evidence Relevance to this page
Greenblatt HK, et al. Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. Curr Opin Rheumatol. 2020;32:289-296. (PMID 32205569) Adjacent evidence from classification-and-diagnosis.md, preclinical-autoimmunity-and-prevention.md
Petrovská N, et al. The pre-clinical phase of rheumatoid arthritis: from risk factors to prevention. Semin Immunopathol. 2021. (PMID 33746022) Adjacent evidence from preclinical-autoimmunity-and-prevention.md
Haville S, et al. Pre-RA: can early diagnosis lead to prevention? Best Pract Res Clin Rheumatol. 2022. (PMID 34991984) Adjacent evidence from preclinical-autoimmunity-and-prevention.md
Rech J, et al. ARIAA abatacept prevention trial. Lancet. 2024. (PMID 38364841) Adjacent evidence from biologic-dmards.md, clinical-trials-landscape.md, epidemiology-and-burden.md, overview.md, preclinical-autoimmunity-and-prevention.md
Cope AP, et al. APIPPRA abatacept prevention trial. Lancet. 2024. (PMID 38364839) Adjacent evidence from biologic-dmards.md, clinical-trials-landscape.md, epidemiology-and-burden.md, overview.md, preclinical-autoimmunity-and-prevention.md
Krijbolder DI, et al. TREAT EARLIER methotrexate proof-of-concept trial. Lancet. 2022. (PMID 35871815) Adjacent evidence from clinical-trials-landscape.md, preclinical-autoimmunity-and-prevention.md
Dumoulin QA, et al. Development of RA after methotrexate in ACPA-negative clinically suspect arthralgia: four-year TREAT EARLIER data. Lancet Rheumatol. 2024. (PMID 39303731) Adjacent evidence from preclinical-autoimmunity-and-prevention.md
Frazzei G, et al. Prevention of rheumatoid arthritis: a systematic literature review. Autoimmun Rev. 2023. (PMID 36280095) Adjacent evidence from overview.md, preclinical-autoimmunity-and-prevention.md
Humby F, et al. R4RA biopsy-driven rituximab versus tocilizumab. Lancet. 2021. (PMID 33485455) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, clinical-trials-landscape.md, epidemiology-and-burden.md, overview.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Rivellese F, et al. Synovial biopsy biomarker analysis of R4RA. Nat Med. 2022. (PMID 35589854) Adjacent evidence from biologic-dmards.md, biomarkers-and-tissue-precision.md, clinical-trials-landscape.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md, treat-to-target-and-remission.md
Atzeni F, et al. Biomarkers in rheumatoid arthritis. Mediators Inflamm. 2017. (PMID 28825772) Adjacent evidence from biomarkers-and-tissue-precision.md, preclinical-autoimmunity-and-prevention.md
Perera J, et al. Seropositive and seronegative RA phenotypes, biomarkers and synovium. 2024. (PMID 38727279) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, overview.md, preclinical-autoimmunity-and-prevention.md
de Pablo P, et al. Imaging tests predicting RA in unclassified arthritis. RMD Open. 2022. (PMID 34782180) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, overview.md, preclinical-autoimmunity-and-prevention.md
Mandl P, et al. Imaging for treat to target in RA. Rheumatology. 2019. (PMID 31518423) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, epidemiology-and-burden.md, overview.md, preclinical-autoimmunity-and-prevention.md, treat-to-target-and-remission.md
He S, et al. Plasma protein biomarkers predating onset and treatment response in RA. 2025. (PMID 40691443) Adjacent evidence from biomarkers-and-tissue-precision.md, preclinical-autoimmunity-and-prevention.md
Ling SF, et al. Pharmacogenetics of methotrexate response in RA. 2020. (PMID 31849277) Adjacent evidence from biomarkers-and-tissue-precision.md, conventional-dmards.md, preclinical-autoimmunity-and-prevention.md
Caproli A, et al. Calprotectin as a biomarker in RA. 2023. (PMID 37584369) Adjacent evidence from biomarkers-and-tissue-precision.md, preclinical-autoimmunity-and-prevention.md
Schonfeldova B, et al. Synovial single-cell heterogeneity and zonation. Nat Rev Rheumatol. 2022. (PMID 34559213) Adjacent evidence from biomarkers-and-tissue-precision.md, preclinical-autoimmunity-and-prevention.md, synovial-immunobiology.md
Grigor C, et al. TICORA tight-control trial. Lancet. 2004. (PMID 15262104) Adjacent evidence from classification-and-diagnosis.md, clinical-trials-landscape.md, epidemiology-and-burden.md, overview.md, preclinical-autoimmunity-and-prevention.md, treat-to-target-and-remission.md
Korpela M, et al. FIN-RACo five-year outcomes. Arthritis Rheum. 2004. (PMID 15248204) Adjacent evidence from classification-and-diagnosis.md, clinical-trials-landscape.md, conventional-dmards.md, epidemiology-and-burden.md, overview.md, preclinical-autoimmunity-and-prevention.md, treat-to-target-and-remission.md
Evidence-map records are listed in full below and were live-retrieved from PubMed in this build session.

Open questions

  • Which mucosal compartment first generates pathogenic autoimmunity in each biological subtype?
  • Does smoking cessation after ACPA emergence reduce progression, and by how much?
  • Can periodontal intervention alter autoantibody maturation or arthritis onset? (Möller 2020, PMID 32582191)
  • Which microbial functions replicate across continents after controlling diet and treatment? (Qi 2025, PMID 40825448)
  • How should multi-ancestry polygenic scores be calibrated without worsening access inequities? (Dedmon 2020, PMID 32638005)
  • Are ACPA-negative disease pathways fundamentally separate or convergent at synovitis? (van Heemst 2014, PMID 24813459)

References

  1. Dedmon LE, et al. The genetics of rheumatoid arthritis. Rheumatology (Oxford). 2020;59:2661-2670. PMID 32638005
  2. Lucchino B, et al. Mucosa-Environment Interactions in the Pathogenesis of Rheumatoid Arthritis. Cells. 2019;8:700. PMID 31295951
  3. Möller B, et al. Infectious Triggers in Periodontitis and the Gut in Rheumatoid Arthritis (RA): A Complex Story About Association and Causality. Front Immunol. 2020;11:1108. PMID 32582191
  4. van Heemst J, et al. HLA and rheumatoid arthritis: how do they connect?. Ann Med. 2014;46:304-10. PMID 24813459
  5. Kadura S, et al. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021;30:210011. PMID 34168062
  6. Kim Y, et al. Etiology and Pathogenesis of Rheumatoid Arthritis-Interstitial Lung Disease. Int J Mol Sci. 2023;24:14509. PMID 37833957
  7. Qi XY, et al. Gut microbiota in rheumatoid arthritis: Mechanistic insights, clinical biomarkers, and translational perspectives. Autoimmun Rev. 2025;24:103912. PMID 40825448
  8. Frade-Sosa B, et al. Neutrophils, neutrophil extracellular traps, and rheumatoid arthritis: An updated review for clinicians. Reumatol Clin (Engl Ed). 2023;19:515-526. PMID 37867028
  9. Aletaha D, et al. Precision medicine and management of rheumatoid arthritis. J Autoimmun. 2020;110:102405. PMID 32276742
  10. Bhamidipati K, et al. Precision medicine in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2022;36:101742. PMID 35248489
  11. Terao C, et al. A twin study of rheumatoid arthritis in the Japanese population. Mod Rheumatol. 2016;26:685-9. PMID 26727555
  12. Jiang X, et al. An Immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis. Rheumatology (Oxford). 2016;55:149-55. PMID 26272072
  13. Mehri F, et al. The association Between Occupational Exposure to silica and Risk of Developing Rheumatoid Arthritis: A Meta-Analysis. Saf Health Work. 2020;11:136-142. PMID 32596007
  14. Morotti A, et al. Systematic Review and Meta-analysis on the Association of Occupational Exposure to Free Crystalline Silica and Rheumatoid Arthritis. Clin Rev Allergy Immunol. 2022;62:333-345. PMID 33651342
  15. Qiao Y, et al. Rheumatoid arthritis risk in periodontitis patients: A systematic review and meta-analysis. Joint Bone Spine. 2020;87:556-564. PMID 32593704
  16. Wang Y, et al. Gut dysbiosis in rheumatic diseases: A systematic review and meta-analysis of 92 observational studies. EBioMedicine. 2022;80:104055. PMID 35594658
  17. Holers VM, et al. Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction. Nat Rev Rheumatol. 2018;14:542-557. PMID 30111803
  18. Svendsen AJ, et al. On the origin of rheumatoid arthritis: the impact of environment and genes--a population based twin study. PLoS One. 2013;8:e57304. PMID 23468964
  19. Greenblatt HK, et al. Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. Curr Opin Rheumatol. 2020;32:289-296. PMID 32205569
  20. Petrovská N, et al. The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmun Rev. 2021;20:102797. PMID 33746022
  21. Haville S, et al. Pre-RA: Can early diagnosis lead to prevention?. Best Pract Res Clin Rheumatol. 2022;36:101737. PMID 34991984
  22. Rech J, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403:850-859. PMID 38364841
  23. Cope AP, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403:838-849. PMID 38364839
  24. Krijbolder DI, et al. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet. 2022;400:283-294. PMID 35871815
  25. Dumoulin QA, et al. Development of rheumatoid arthritis after methotrexate in anticitrullinated protein antibody-negative people with clinically suspect arthralgia at risk of rheumatoid arthritis: 4-year data from the TREAT EARLIER trial. Lancet Rheumatol. 2024;6:e827-e836. PMID 39303731
  26. Frazzei G, et al. Prevention of rheumatoid arthritis: A systematic literature review of preventive strategies in at-risk individuals. Autoimmun Rev. 2023;22:103217. PMID 36280095
  27. Humby F, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397:305-317. PMID 33485455
  28. Rivellese F, et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022;28:1256-1268. PMID 35589854
  29. Atzeni F, et al. Biomarkers in Rheumatoid Arthritis. Isr Med Assoc J. 2017;19:512-516. PMID 28825772
  30. Perera J, et al. Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review. Cells. 2024;13:743. PMID 38727279
  31. de Pablo P, et al. Systematic review of imaging tests to predict the development of rheumatoid arthritis in people with unclassified arthritis. Semin Arthritis Rheum. 2022;52:151919. PMID 34782180
  32. Mandl P, et al. The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford). 2019;58:2091-2098. PMID 31518423
  33. He S, et al. A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis. Nat Commun. 2025;16:6692. PMID 40691443
  34. Ling SF, et al. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update. Pharmacogenomics. 2020;21:3-6. PMID 31849277
  35. Caproli A, et al. Calprotectin as a biomarker in rheumatoid arthritis: the potential predictive value of response to treatment. Bioanalysis. 2023;15:1111-1113. PMID 37584369
  36. Schonfeldova B, et al. Synovial single-cell heterogeneity, zonation and interactions: a patchwork of effectors in arthritis. Rheumatology (Oxford). 2022;61:913-925. PMID 34559213
  37. Grigor C, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9. PMID 15262104
  38. Korpela M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50:2072-81. PMID 15248204